Toxicology of Organophosphate Nerve Agents

Chemical Warfare Agents: Toxicology and Treatment, Second Edition

Volumn , Issue , 2007, Pages 191-221

  Marrs, Timothy C ^a,b,c  

^a Edentox Associates   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Acute toxicity; Cholinergic neurotransmission; Nerve agent induced delayed polyneuropathy; Organophosphate nerve agent toxicology; Organophosphate induced delayed polyneuropathy (OPIDP)

Indexed keywords

EID: 80052319984     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470060032.ch8     Document Type: Chapter

References (242)

1. Aldridge WN. (1950). Some properties of specific cholinesterase with particular reference to the mechanism of inhibition of diethyl p-nitrophenyl thiophosphate (E605) and analogues. Biochem J, 46, 451-460.
2. Aldridge WN, Barnes JM and Johnson MK. (1969). Studies on delayed neuropathy produced by some organophosphorus compounds. Ann NY Acad Sci, 160, 314-322.
3. Anderson RJ and Dunham CB. (1985). Electrophysiologic changes in peripheral nerve following repeated exposure to organophosphorus agents. Arch Toxicol, 58, 97-101.
4. Anderson DR, Harris LW, Chang F-C et al. (1997). Antagonism of soman-induced convulsions by midazolam, diazepam and scopolamine. Drug Chem Toxicol, 20, 115-131.
5. Annau Z (1992). Neurobehavioral effects of organophosphorus compounds. Organophosphates, Chemistry, Fate and Effects (JE Chambers and PE Levi, eds), pp. 419-432. San Diego, CA, USA: Academic Press.
6. Anthony JS, Haley M, Manthei J et al. (2004). Inhalation toxicity of cyclosarin (GF) vapour in rats as a function of exposure concentration and duration: potency comparison to sarin (GB). Inhalation Toxicol, 16, 103-111.
7. Anzueto A, Berdine GG, Moore GT et al. (1986). Pathophysiology of soman intoxication in primates. Toxicol Appl Pharmacol, 86, 56-68.
8. Ariens AT, Wolthuis OL and van Bentham RMJ. (1969). Reversible necrosis at the end plate region in striated muscles of the rat poisoned with cholinesterase inhibitors. Experientia, 1, 57-59.
9. Bajgar J, Sevelová L, Krejčová G et al. (2004). Biochemical and behavioural effects of soman vapors in low concentrations. Inhal Toxicol, 16, 497-507.
10. Bakri NMS, El-Rashidi AH, Eldefrawi AT et al. (1988). Direct actions of organophosphate anticholinesterases on nicotinic and muscarinic actylcholine receptors. J Biochem Toxicol, 3, 235-239.
11. Bakshi KS, Pang SNJ and Snyder R. (2000). Introduction to the special issue. J Toxicol Environ Health A, 59, 283-288.
12. Ballantyne B (1992). Forensic aspects of acute anticholinesterase poisoning. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs, eds), pp. 618-622. Oxford: Butterworth-Heinemann.
13. Ballantyne B and Marrs TC (1992). Overview of the biological and clinical aspects of organophosphates and carbamates. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs, eds), pp. 1-14. Oxford: Butterworth-heinemann.
14. Barak D, Ordentlich A, Kaplan D et al. (2000). Evidence for P-N bond scission in phosphoramidate nerve agent adducts of human acetylcholinesterase. Biochemistry, 8, 1156-1161.
15. Beesley WN (1994). Sheep dipping, with special reference to the UK. Pesticides Outlook, February, 16-29.
16. Benschop HP, Bijleveld EC, de Jong LPAet al. (1987). Toxicokinetics of the four stereoisomers of the nerve agent soman in atropinized rats-influence of a soman simulator. Toxicol Appl Pharmacol, 90, 490-500.
17. Berry WK and Davies DR. (1970). Use of carbamates and atropine in the protection of animals against poisoning by 1,2,2-trimethylpropyl phosphonofluoridate. Biochem Pharmacol, 19, 927-934.
18. Black RM, Harrison JM and Read RW (1999). The interaction of sarin and soman with plasma proteins: the identification of a novel phosphonylation site. Arch Toxicol, 73, 123-126.
19. Bosković B, Kovacević V and Jovanović D. (1984). 2-PAM chloride, H16 and HGG 12 in soman and tabun poisoning. Fund Appl Toxicol, 4, 106-115.
20. Bourne Y, Taylor P and Marchot P. (1995). Acetylcholinesterase inhibition by fasciculin, crystal structure of the complex. Cell, 83, 503-512.
21. Bourne Y, Taylor P, Bougis PE et al. (1999). Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly. J Biol Chem, 274, 2963-2970.
22. Bowman WC. (1993). Physiology and pharmacology of neuromuscular transmission, with special reference to the possible consequences of prolonged blockade. Intensive Care Med, 19, S45-S53.
23. Boyd RT. (1997). The molecular biology of neuronal nicotinic acetylcholine receptors. Crit Rev Toxicol, 27, 299-318.
24. Braitman DJ and Sparenborg S. (1989). MK-801 protects against seizures induced by the cholinesterase inhibitor soman. Brain Res Bull, 23, 145-148.
25. Brezenoff HE, McGee J and Knight V. (1984). The hypertensive response to soman and its relation to brain acetylcholinesterase inhibition. Acta Pharmacol Toxicol, 55, 270-277.
26. Bright JE, Inns RH, Tuckwell NJ et al. (1991).Ahistochemical study of changes observed in the mouse diaphragm after organophosphate poisoning. Human Exp Toxicol, 10, 9-14.
27. Brimblecombe RW (1974). Drug Actions in Cholinergic System, pp. 64-132. New York: MacMillan.
28. Brimblecombe RW, Green DM, Stratton JA et al. (1970). The protective actions of some anticholinergic drugs in sarin poisoning. Brit J Pharmacol, 39, 822-830.
29. Britt JO, Martin JL, Okerberg CV et al. (2000). Histopathologic changes in the brain, heart and skeletal muscle of rhesus macaques ten days after exposure to soman (an organophsophorus nerve agent). Comp Med, 50, 133-139.
30. Brock A and Brock V. (1993). Factors affecting interindividual variation in human plasma cholinesterase activity: body weight, height, sex, genetic polymorphisms and age. Arch Environ Contam Toxicol, 24, 93-99.
31. Brown MA and Brix KA. (1998). Review of health consequences from high-, intermediate-and lowlevel exposure to organophosphorus nerve agents. J Appl Toxicol, 18, 393-408.
32. Burchfiel JL, Duffy FH and Sim van M. (1976). Persistent effects of sarin and dieldrin upon the primate electroencephalogram. Toxicol Appl Pharmacol, 35, 365-379.
33. Burgen ASV and Hobbiger F. (1951). The inhibition of cholinesterases by alkylphosphates and alkylphenophosphates. Br J Pharmacol Chemother, 6, 593-605.
34. Cabal J, Kuca K and Kassa J. (2004). Specification of the structure of oximes able to reactivate tabuninhibited acetylcholinesterase. Basic Clin Pharmacol Toxicol, 95, 81-86.
35. Casida JE and Quistad GB. (2004). Organophosphate toxicology: safety aspects of nonacetylcholinesterase secondary targets. Chem Res Toxicol, 17, 983-997.
36. Chambers HW (1992). Organophosphorus compounds: an overview. In: Organophosphates, Chemistry, Fate and Effects. (JE Chambers and PE Levi, eds), pp. 3-18. San Diego, CA, USA: Academic Press.
37. Chang F-CT, Foster RE, Beers ET et al. (1990). Neurophysiological concomitants of soman-induced respiratory depression in awake, behaving guinea pigs. Toxicol Appl Pharmacol, 102, 233-250.
38. Chatthopadhay DP, Dighe SK, Nashikkar AB et al. (1986). Species differences in the in vitro inhibition of grain acetylcholinesterase and carboxyl esterase by mipafox, paraoxon and soman. Pest Biochem Physiol, 26, 202-208.
39. Chechabo SR, Santos MD and Albuquerque EX. (1999). The organophosphate sarin, at low concentrations, inhibits the evoked release of GABA in rat hippocampal slices. Neurotoxicology, 20, 871-882.
40. Cherry NM, Durrington PN, Mackness B et al. (2005). Genetic variation in susceptibility to chonic effects of organophosphate exposure. Health and Safety Executive Research Report 408. London, Edinburgh, Belfast, UK: Her Majesty's Stationary Office.
41. Clement JG. (1984). Role of aliesterase in organophosphate poisoning. Fund Appl Toxicol, 4, S96-S105.
42. Clement JG. (1992). Efficacy of various oximes against GF (cyclohexylmethylphosphonofluoridate) poisoning in mice. Arch Toxicol, 66, 143-144.
43. Clement JG, Hand BT and Shiloff JD. (1981). Differences in the toxicity of soman in various strains of mice. Fund Appl Toxicol, 1, 419-420.
44. Coleman IW, Little PE, Patton GE et al. (1966). Cholinolytics in the treatment of anticholinesterase poisoning IV. The effectiveness of five binary combinations of cholinolytics with oximes in the treatment of organophosphorus poisoning. Can J Physiol Pharmacol, 44, 743-764.
45. Coleman IW, Patton GE and Bannard RA. (1968). Cholinolytics in the treatment of anticholinesterase poisoning V. The effectiveness of parpanit with oximes in the treatment of organophosphorus poisoning. Can J Physiol Pharmacol, 46, 109-117.
46. Committee on Toxicity of Products in Food, Consumer Products and the Environment (1999). Organophosphates, Report of the Committee on Toxicity of Products in Food, Consumer Products and the Environment. London, UK: Department of Health.
47. Costa LG, Li WF, Richter RJ et al. (1999). The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem-Biol Interact, 119/120, 429-438.
48. Costa LG, LiW-F, Richter RJ et al. (2002). PON1 and organophosphate toxicity. In:Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects (LG Costa and CE Furlong, eds), pp. 165-184.Dordrecht, The Netherlands: Kluwer Academic Publishers.
49. Costa LG, Cole TB and Furlong CE. (2003). Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. J Toxicol Clin Toxicol, 41, 37-45.
50. Costa LG, Cole TB, Vitalone A et al. (2005). Paraoxonase polymorphisms and toxicity of organophosphates. In: Toxicology of Organophosphate and Carbamate Compounds. (R Gupta, ed.) pp. 247-255. San Diego, CA, USA: Academic Press.
51. Crouzier D, Baille le CromV, Four E et al. (2004). Disruption of mice sleep stages induced by low doses of organophosphorus compound soman. Toxicology, 199, 59-71.
52. Crowell JA, Parker RM, Bucci TJ et al. (1989). Neuropathy terget esterase in hens after sarin and soman, J Biochem Toxicol, 4, 15-20.
53. Curtil C and Masson P. (1993). Le vieillissement des cholinesterase après inhibition par les organophosphorés. Ann Pharmacoceut Franç, 51, 63-77.
54. Denk JR (1975). Effect of GB on mammalian germ cells and reproductive parameters, Final report EB-TR-74087, AD-A006503. Aberdeen Proving Ground, Fort Detrick, MD, USA: US Army Medical Research and Development Command.
55. DiGiovanni C. (1999). Domestic terrorism with chemical or biological agents: psychiatric aspects. Am J Psychiatr, 156, 1500-1505.
56. Dittmann E and Wiegand C. (2005). Cyanobacterial toxins-occurrence, biosynthesis and impact on human affairs. Mol Nutr Food Res, 50, 7-17.
57. D'Mello GD. (1993). Behavioural toxicity of anticholinesterases in humans and animals-a review. Human Exp Toxicol, 12, 3-7.
58. D'Mello GD and Duffy EAM. (1985). The acute toxicity of sarin in marmosets (Callithrix jacchus): a behavioral analysis. Fund Appl Toxicol, 5, S169-S174.
59. Duffy FH, Burchfiel JL, Bartels PH et al. (1979). Long-term effects of an organophosphate upon the human electroencephalogram. Toxicol and Appl Pharmacol, 47, 161-176.
60. Eglen RM and Whiting RL. (1990). Heterogeneity of vascular muscarinic receptors. J Autonom Pharmacol, 10, 233-245.
61. Ekstrom F, Akfur C, Tunemalm AK et al. (2006). Structural changes of phenylalanine 338 and histidine 447 revealed by the crystal structures of tabun-inhibited murine acetylcholinesterase. Biochemistry, 10, 74-81.
62. Eldefrawi AT, Jett D and Eldefrawi ME (1992). Direct actions of organophosphorus anticholinesterases on muscarinic receptors. In: Organophosphates, Chemistry, Fate and Effects (JE Chambers and PE Levi, eds), pp. 268-323. San Diego, CA, USA: Academic Press.
63. Ellman GL, Courtney D and Andres V. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharamcol, 7, 88-95.
64. Feldman RG (1999). Occupational and Environmental Neurotoxicology, p. 432. Philadelphia, PA, USA: Lippincott-Raven.
65. Fenner-Crisp P, Adams J, Balbus J et al.. (2005). Application of developmental neurotoxicity testing to public health protection. Neurotoxicol Teratol, 27, 371.
66. Filliat P, Baubichon D, Burckhart M-F et al. (1999). Memory impairment after soman intoxication in rat: correlation with central neuropathology. Improvement with anticholinergic and antiglutamatergic therapeutics. Neurotoxicol, 20, 535-550.
67. Fleisher JH, Harris LW, Prudhomme C et al. (1963). Effects of p-nitrophenyl phosphonate (EPN) on the toxicity of isopropyl methyl phosphonofluoriate (GB). J. Pharmacol Exp Ther, 139, 390-396.
68. Fletcher HP, Noble S and Spratto GR. (1989). Effect of the acetylcholinesterase inhibitor, soman, on plasma levels of endorphin and adrenocorticotrophic hormone (ACTH). Biochem Pharmacol, 38, 2045-2046.
69. Fosbraey P,Wetherell JR and French MC (1990). Neurotransmitter changes in guinea-pig brain regions following soman intoxication. J Neurochem, 54, 72-79.
70. Fredriksson T. (1957). Pharmacological properties of methyl fluorophosphomylcholines-two synthetic cholinergic drugs. Arch Int Pharmacol Ther, 113, 101-104.
71. Ganong WF (1991). Review of Medical Physiology, 15th Edition. Paramus, NJ, USA: Prentice Hall International Ltd.
72. Gates M and Renshaw BC (1946). Fluorophosphates and other phosphorus-containing compounds. In: Summary Technical Report of Division 9, Vol. 1, Parts I, II, pp. 131-155. Washington, DC, USA: Office of Scientific Research and Development.
73. George KM, Schule T, Sandoval LE et al. (2003). Differentiation between acetylcholinesterase and the organophosphate-inhibited form using antibodies and the correlation of antibody recognition with reactivation mechanism and rate. J Biol Chem, 278, 45512-45518.
74. Glynn P. (2000). Neural development and neurodegeneration: two faces of neuropathy target esterase. Prog Neurobiol, 61, 61-74.
75. Goldman M, Wilson BW, Kawakami TG et al. (1988). Toxicity studies on agent VX, Final Report, DTIC AD-A201397. Fort Detrick, MD, USA: US Army Medical Research and Development Command.
76. Goldstein BD, Fincher DR and Searle JR. (1987). Electrophysiological changes in the primary sensory neuron following subchronic soman and sarin: aletations in sensory receptor function. Toxicol Appl Pharmacol, 91, 55-64.
77. Gordon JJ, Inns RH, Johnson MKet al. (1983). The delayed neuropathic effects of nerve agents and some other organophosphate compounds. Arch Toxicol, 51, 71-82.
78. Gordon JJ and Leadbeater LL. (1977). The prophylatic use of (1-methyl 2-hydroxy-iminomethylpyridinium methanesulfonate) (P2S) in the treatment of organophosphate poisoning. Toxicol Appl Pharmacol, 40, 109-114.
79. Gray AP. (1984). Design and structure-activity relationships of antidotes to organophosphorus anticholinesterase agents. Drug Metab Rev, 15, 557-589.
80. Gray PJ and Dawson RM. (1987). Kinetic constants for the inhibition of eel and rabbit brain acetylcholinesterase by some organophosphates and carbamates of military significance. Toxicol Appl Pharmacol, 91, 140-144.
81. Grob D and Harvey AM. (1953). The effects and treatment of nerve gas poisoning. Am J Med, 14, 52-63.
82. Grob D and Harvey AM. (1958). Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). J Clin Invest, 37, 350-368.
83. gulflink (2005). http:/www.gulflink.osd.mil/library/randrep/mr1018.5.appb.pdf, accessed 14th December 2005.
84. Gupta RC, Patterson GT and Dettbarn W-D (1987a). Acute tabun toxicity; biochemical and histochemical consequences in brain and skeletal muscles of rats. Toxicology, 46, 329-341.
85. Gupta RC, Patterson GT and Dettbarn W-D (1987b). Biochemical and histochemical alterations following acute soman intoxication in the rat. Toxicol Appl Pharmacol, 87, 393-402.
86. Guzelian PS, Henry CJ and Olin SS (1992). Similarities and Differences between Children and Adults: Implications for Risk Assessment. Washington, DC, USA: ILSI Press.
87. Haley RW. (2000). PON1 and low dose sarin in marmosets. J Psychopharm, 14, 87-88.
88. Haley RW, Billecke S and La Du BN. (1999). Association of low PON1 type Q (type A) arylesterase activity with neurological symptom complexes in Gulf war veterans. Toxicol Appl Pharmacol, 157, 227-233.
89. Harris LW,Heyl WC, Stitcher DLet al. (1978). Effects of 1,1'-oxydimethylene bis (4-tert-butylpyridinium chloride (SAD-128) and decamethonium on reactivation of soman and sarin-inhibited cholinesterase by oximes. Biochem Pharmacol, 27, 757-761.
90. Hatta K, Miura Y, Asukai N et al.. (1996). Amnesia from sarin poisoning. Lancet, 347, 1343.
91. Heilbronn E. (1963). In vitro reactivation and aging of tabun-inhibited blood cholinesterases: studies with N-methylpyridinium-2-aldoxime methane sulphonate and N, N'-trimethylene bis (pyridinium-4-aldoxime) dibromide. Biochem Pharmacol, 12, 25-36.
92. Henderson JD, Higgins RJ, Dacre JC et al. (1992). Neurotoxicity of acute and repeated treatments of tabun, paraoxon, diisopropyl fluorophosphate and isofenphos to the hen. Toxicology, 72, 117-129.
93. Holmes JH and Gaon MD. (1956). Observations on acute and multiple exposure to anticholinesterase agents. Trans Am Clin Chem Assoc, 68, 86-103.
94. Hughes JN, Knight R, Brown RFR et al. (1991). Effects of experimental sarin intoxication on the morphology of the mouse diaphragm: a light and electron microscopical study. Int J Exp Path, 72, 195-209.
95. Inns RH, Tuckwell NJ, Bright JE et al. (1990). Histochemical demonstration of calcium accumulation in muscle fibres after experimental organophosphate poisoning. Human Exp Toxicol, 9, 245-250.
96. Institute of Medicine (1996). Health Consequences of Service during the Persian Gulf War: Recommendations for Research and Information Systems. Washington, DC, USA: National Academy Press.
97. Jamal GA. (1995). Long-term neurotoxic effects of organophosphate compounds. Adv Drug React Toxicol Rev, 14, 85-99.
98. Jimmerson VR, Shih T-M and Mailman RB. (1989). Variability in soman toxicity in the rat: correlation with biochemical and behavioral measures. Toxicology, 57, 241-254.
99. Johnson MK. (1975). Organophosphorus esters causing delayed neurotoxic effects. Arch Toxicol, 34, 259-288.
100. Johnson MK, Willems JL, de Bisschop HC et al. (1985). Can soman cause delayed neuropathy? Fund Appl Toxicol, 5, S180-S181.
101. Jones SV. (1993). Muscarinic receptor subtypes: modulation of ion channels. Life Sci, 52, 457-464.
102. Jovanović D. (1982). The effect of bis-pyridirium oximes on neuromuscular blockade induced by highly toxic organophosphates in the rat. Arch Int Pharmacol Ther, 262, 231-241.
103. Kaminski HJ and Ruff RL (1999). Structure and kinetic properties of the acetylcholine receptor. In: Myasthenia and Myasthenic Disorders (AG Engel, ed.), pp. 40-64. New York, Oxford University Press.
104. Karalliedde L. (2002). Cholinesterase estimations revisited: the clinical relevance. Eur J Anaesthesiology, 19, 313-316.
105. Karalliedde L, Wheeler H, Maclehose R et al. (2000). Possible intermediate and long-term health effects following exposure to chemical warfare agents. Public Health, 114, 238-248.
106. Karalliedde L, Baker D and Marrs TC. (2006). Organophosphate-induced intermediate syndrome: its aetiology and the relationship with myopathy. Toxicol Rev, 25, 1-14.
107. Kassa J and Cabal J. (1999). A comparison of the efficacy of actylcholinesterase reactivators against cyclohexylmethylphosphonofluoridate (GF agent) by in vitro and in vivo methods. Pharmacol Toxicol, 84, 41-45.
108. Kassa J, Krejčová G, Skopek F et al. (2004). The influence of sarin on various physiological functions in rats following single or repeated low-level exposure. Inhal Toxicol, 16, 517-530.
109. Kitos PA and Suntornwat O (1992). Teratogenic effect of organophosphorus compounds. In: Organophosphates, Chemistry, Fate and Effects (JE Chambers and PE Levi, eds), pp. 387-417. San Diego, CA, USA: Academic Press.
110. Klein AK, Nasr ML and Goldman M. (1987). The effects of in vitro exposure to the neurotoxins sarin (GB) and soman (GD) on unscheduled DNA synthesis by rat hepatocytes. Toxicol Lett, 38, 239-249.
111. Koelle GB (1992). Pharmacology and toxicology of organophosphates. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs eds), pp. 33-37. Oxford, UK: Butterworth-Heinemann.
112. Koplovitz I, Gresham VC, Dochterman LW et al. (1992). Evaluation of the toxicity, pathology and treatment of cyclohexylmethylphosphonofluoridate (CMPF) poisoning in rhesus monkeys. Arch Toxicol, 66, 622-628.
113. Korsak RJ and Sato MM. (1977). Effects of chronic organophosphate pesticide exposure on the central nervous system. Clin Toxicol, 11, 83-95.
114. Kovacic P. (2003). Mechanism of organophosphates (nerve gases and pesticides) and antidotes: electron transfer and oxidative stress. Curr Med Chem, 16, 2705-2709.
115. La Borde JB and Bates HK (1986). Developmental toxicity study on agent GB-DCSM types I and II in CD rats and NZW rabbits, Final Report. Fort Detrick, MD, USA: US Army Medical Research and Development Command.
116. Lader M (2001). The effects of organophosphates on neuropsychiatric and psychological function. In: Organophosphates and Health (L Karalliedde, S Feldman, J Henry and T Marrs, eds), pp. 175-198. London, UK: Imperial College Press.
117. Lau W-M, Freeman SE and Szilagyí M. (1988). Binding of some organophosphorus compounds at adenosine receptors in guinea pig brain membranes. Neurosci Lett, 94, 125-130.
118. Lawler HC. (1961). Turnover time of actylcholinesterase. J Biol Chem, 236, 2296-2301.
119. Lebeda FJ, Wierwille RC, VanMeter WG et al. (1988). Acute ultrastructural alterations in duced by soman and hypoxia in rat hippocampal CA3 pyramidal neurones. NeuroToxicol, 9, 9-22.
120. Leblic C, Cox HM and le Moan L (1984). Etude de la toxicité, de l'eserine, VX et le paraoxon, pourétablir un modéle mathematique de l'extrapolationà ̂etre humain. Arch Blg Med Soc Hyg Trav Med (Supplement), 226-242.
121. le Cĥene E (1989). Chemical and Biological warfare-Threat of the Future, Mackenzie Paper. Toronto, Canada: The Mackenzie Institute.
122. Lefkowitz RJ, Hoffnman BB and Taylor P (1996). Drugs acting at synaptic and neuroeffector junctional sites. In: Goodman and Gilman's Pharmacological Basis of Therapeutics, 9th Edition (JG Hardman, LE Limbird, PB Molinoff, RW Rudden and AG Gilman, eds), pp. 105-140. New York, NY, USA: McGraw-Hill.
123. Leonard JP and Salpeter MM (1979). Agonist induced myopathy at the neuromuscular junction is mediated by calcium. J Cell Biol, 82, 811-819.
124. Li Q, Minami M, Clement JG et al. (1998). Elevated frequency of sister chromatid exchanges in lymphocytes of victims of the Tokyo sarin disaster and in experiments exposing lymphocytes to byproducts of sarin synthesis. Toxicol Lett, 98, 95-103.
125. Ligtenstein DA (1984). On the synergism of the cholinesterase reactivating bispyridiniumaldoxime HI-6 and atropine in the treatment of organophosphate intoxications in the rat, MD Thesis. Leyden, the Netherlands: University of Leyden.
126. Lipp SA. (1972). Effect of diazepam upon soman induced seizure activities and convulsions. Electroenceph Clin Neurophysiol, 32, 557-560.
127. Lockridge O and Schopfer LM (2005). Biomarkers of organophosphate exposure. In: Toxicology of Organophosphate and Carbamate Compounds (R Gupta, ed.), pp. 703-711. San Diego, CA, USA: Academic Press.
128. Lotts von K. (1960). Zur Toxikologie and pharmakologie organischer Phosphosäurester. Dtsch Gesundheitsweren, 15, 2179-2133.
129. Ludomirsky A, Klein HO and Sarelli P. (1982). QT Prolongations and polymorphous ('torsade de pointes') ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am J Cardiol, 49, 1654-1658.
130. Lundy PM, Hansen AS, Hand BT et al. (1992). Comparison of several oximes against poisoning by soman, tabun and GF. Toxicology, 72, 99-105.
131. Main AR and Iverson F. (1966). Measurement of the affinity and phosphorylation onstants governing irreversible inhibition of cholinesterases by diisopropyl phosphoofluoridate. Biochem J, 100, 525-531.
132. Makris S (2005). Regulatory considerations in developmental neurotoxicity of organophosphorus and carbamate pesticides In: Toxicology of Organophosphate and Carbamate Compounds (R Gupta, ed.), pp. 633-642. San Diego, CA, USA: Academic Press.
133. Maksimović M, Bosković B, Rodović L et al. (1980). Antidotal effects of bis-pyridinium 2-mono oxime carbonyl derivatives in intoxication with highly toxic organophosphorus compounds. Acute Pharm Jagoslav, 30, 151-160.
134. Marrs TC (2001). Organophosphates: history, chemistry, pharmacology. In: Organophosphates and Health (L Karalliedde, S Feldman, J Henry and T Marrs, eds), pp. 1-37. London, UK: Imperial College Press.
135. Marrs TC and Bright JE (1992). Histochemical localization of cholinesterase in anticholinesterase poisoning. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs, eds), pp. 28-43. Oxford, UK: Butterworth-Heinemann.
136. Marrs TC and Maynard RL (1994). Neurotoxicity of chemical warfare agents. In: Handbook of Clinical Neurology, Part 1, Volume 64. (PJ Vinken, GW Bruyn and FA de Wolff, eds), pp. 223-247. Amsterdam, The Netherlands: Elsevier.
137. Marrs TC and Maynard RL (2001). Organophosphorus chemicalwarfare agents. In: Organophosphates and Health. (LKaralliedde, S Feldman, J Henry and T Marrs, eds), pp. 83-108. London, UK: Imperial College Press.
138. Marrs TC, Bright JE, Inns RH et al.. (1990). Histochemical demonstration of calcium influx into mouse diaphragms induced by sarin. Toxicologist, 10, 132.
139. Marrs TC, Karalliedde L and Baker D (2005). Intermediate Syndrome, does it exist? Can it be prevented?. Toxicology, 213, 208.
140. Martin LJ, Doebbler JA, Shih T-M et al. (1985). Protective effect of diazepam pretreatment on soman-induced brain lesion formation. Brain Res, 325, 287-289.
141. Masuda N, Takatsu M, Morinari H et al.. (1995). Sarin poisoning on the Tokyo subway. Lancet, 345, 1446.
142. Maxwell DM and Lenz DE (1992). Structure-activity relationships and anticholinesterase activity. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates. (B Ballantyne and TC Marrs, eds), pp. 47-58. Oxford, UK: Butterworth-Heinemann.
143. Maynard RL (1999). Toxicology of chemical warfare agents. In: General and Applied Toxicology. (B Ballantyne, TC Marrs and T Syversen, eds), pp. 2079-2109. Basingstoke, UK: MacMillan.
144. Maynard RL and Beswick FW (1992). Organophosphorus compounds as chemical warfare agents. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates. (BBallantyne and TC Marrs, eds), pp. 373-385. Oxford, UK: Butterworth-Heinemann.
145. McDonough JH, Jaax NK, Crowley RA et al. (1989). Atropine and/or diazepam therapy protects against soman-induced neural and cardiac pathology. Fund Appl Toxicol, 13, 256-276.
146. McDonough JH, Smith RF and Smith CD. (1986). Behavioral correlates of soman-induced neuropathology: deficits in DRL acquisition. Behav Toxicol Teratol, 8, 179-187.
147. McElhatton P. (1987). Personal communication cited in Minton NA and Murray VSG (1988).Areviewof organophosphate poisoning. Med Toxicol, 3, 350-375.
148. McLeod CG. (1985). Pathology of nerve agents: perspectives on medical management. Fund Appl Toxicol, 5, S10-S16.
149. Millard CB, Kryger G, Ordentlich A et al. (1999). Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level. Biochemistry, 38, 7032-7039.
150. Minton NA and Murray VSG. (1988). A review of organophosphate poisoning. Med Toxicol, 3, 350-375.
151. Misulis KE, Clinton ME, Dettbarn W-D et al. (1987). Differences in central and peripheral neural actions between soman and diisopropyl fluorophosphate, organophosphorus inhibitors of acetylcholinesterases. Toxicol Appl Pharmacol, 89, 391-398.
152. Mobley PL (1990). The cholinesterase inhibitor soman increases inositol triphosphate in rat brain. Neuropharmacology, 29, 189-191.
153. Moore DH (1998). Health effects of exposure to low doses of nerve agent-a review of present knowledge. Drug Chem Toxicol, 21 (Supplement 1), 123-130.
154. Munro NB, Talmage SS, Griffin GD et al. (1999). The sources, fate, and toxicity of chemical warfare agent degradation products. Environ Health Perspect, 107, 933-974.
155. Murata K, Araki S,YokoyamaKet al. (1997). Asymptomatic sequelae to acute sarin poisoning in the central and autonomic nervous system 6 months after the Tokyo subway attack. J Neurol, 244, 601-666.
156. Nagao M, Takatori T, Matsuda Y et al. (1997). Definitive evidence for the acute sarin poisoning diagnosis in the Tokyo subway. Toxicol Appl Pharmacol, 144, 198-203.
157. Nakajima T, Sato S, Morita H et al. (1997). Sarin poisoning of a rescue team in the Matsumoto sarin incident in Japan. Occ Environ Med, 54, 697-701.
158. Nakajima T, Sasaki K, Ozawa H et al. (1998). Urinary metabolites of sarin in a patient of the Matsumoto sarin incident. Arch Toxicol, 72, 601-603.
159. Naseem SM (1990). Effect of organophosphates on dopamine and muscarinic receptor binding in rat brain Biochem Int, 20, 799-806.
160. National Academy of Sciences (1982). Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents, Volume 1, Anticholinesterases and Anticholinergics. Washington, DC, USA: National Academy Press.
161. Nishiwaki Y, Maekawa K, Ogawa Y et al. (2001). Effects of sarin on the nervous system in resuce team staff members and police officers 3 years after the Tokyo sarin attack. Environ Health Perspect, 109, 1169-1173.
162. Nohara M and Segawa K. (1996). Ocular symptoms due to organophosphorus gas (Sarin) poisoning in Matsumoto. Brit J Ophthalm, 80, 1023.
163. Noort D, Hulst AG, Platenburg DHJM et al. (1998). Quantitative analysis of O-isopropyl methylphosphonic acid in serum samples of Japanese citizens exposed to sarin: estimation of internal dosage. Arch Toxicol, 72, 671-675.
164. Noort D, Benschop HP and Black RM. (2002). Biomonitoring of exposure to chemical warfare agents: a review. Toxicol Appl Pharmacol, 184, 116-126.
165. Nozaki H, Aikawa N, Fujishima S et al. (1995). A case of VXpoisoning and the difference from sarin. Lancet, 346, 698-699.
166. O'Brien RD (1976). Acetylcholinesterase and its inhibition. In: Insecticides Biochemistry and Physiology. (CF Wilkinson, ed.), pp. 271-296. New York, NY, USA: Plenum Press.
167. Oda Y (1999). Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int, 49, 921-937.
168. OECD (2003). Developmental Neurotoxicity Study, Draft New Guideline 426, September. Paris, France: Organization for Economic Co-operation and Development.
169. Ohbu S,Yamashina A, Takasu N (1997). Sarin poisoning on Tokyo subway. Southern Med J, 90, 587-593.
170. Okudera H. (2002). Clinical features on nerve gas terrorism in Matsumoto. J Clin Neurosci, 9, 17-21.
171. O'Leary TF, Kunkel AM and Jones AH. (1961). Efficacy and limitations of oxime-atropine treatment of organophosphorus anticholinesterase poisoning. J Pharmacol Exp Ther, 132, 50-52.
172. Ortells MO and Lunt GG. (1995). Evolutionary history of the ligand-gated ion-channel superfamily of receptors. Trends Neurosci, 18, 121-127.
173. Østergaard D, Jensen FS and Viby-Morgensen J (1992). Pseudocholinesterase deficiency and anticholinesterase toxicity. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs, eds), pp. 520-527. Oxford, UK: Butterworth-Heinemann.
174. Padzernik TL, Cross R, Nelson S et al. (1983). Soman-induced depression of grain activity in TAB-pretreated rats: 2-dooxyglucose study. Neurotoxicity, 4, 27-34.
175. Parker RM, Crowell JA, Bucci TJ et al.. (1988). Negative delayed neuropathy study in chickens after treatment with isopropyl methylphosphonofluoridate (sarin, type 1). Toxicologist, 8, 248.
176. Pearce PC, Crofts HS, Muggleton NG et al. (1999). The effects of acutely administered low dose sarin on cognitive behaviour and the electroencephalogram in the common marmoset. J Psychopharmacol, 13, 128-135.
177. Pelkonin O, Vähäkangas K and Gupta RC (2005). Placental toxicity of organophosphate and carbamate pesticides. In: Toxicology of Organophosphate and Carbamate Compounds (R Gupta, ed.), pp. 463-479. San Diego, CA, USA: Academic Press.
178. Petras JM. (1981). Soman neurotoxicity. Fund Appl Toxicol, 1, 242.
179. Petty CS. (1958). Histochemical proof of organic phosphate poisoning. Arch Pathol, 66, 458-463.
180. Pimentel JH and Carrington da Costa RB (1992). Effects of organophosphates on the heart. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs, eds), pp. 145-148. Oxford, UK: Butterworth-Heinemann.
181. Preusser H-J. (1967). Die Ultrastructur der motorischen Endplatte im Zwerchfell der Ratte und Veranderungen nach Inhibierung der Acetylcholinesterase. Zeit Zellforsch, 80, 436-457.
182. Qiao D, Seidler FJ and Slotkin TA. (2001). Developmental neurotoxicity of chlorpyrifos modelled in vitro: comparative effects of metabolites and other cholinesterase inhibitors on DNA synthesis in PC12 and C6 cells. Environ Health Perspect, 109, 909-913.
183. Raveh L, Chapman S, Cohen G et al. (1999). The involvement of the NDMA receptor complex in the protective effect of anticholinergic drugs against soman poisoning. Neurotoxicology, 20, 551-510.
184. Ray D (1998a). Organophosphate Esters, Report prepared for the Department of Health. Leicester, UK: Institute for Environment and Health.
185. Ray D (1998b). Chronic effects of low level exposure to anticholinesterases-a mechanistic review. Toxicol Lett, 102/103, 527-533.
186. Rengstorff HH. (1985). Accidental exposure to sarin: vision effects. Arch Toxicol, 56, 201-203.
187. Reutter S. (1999). Hazards of chemical weapons release duringwar: newperspectives. Environ Health Perspect, 107, 985-990.
188. Richards P, Johnson M, Ray D et al. (1999). Novel targets for organophosphorus compounds. Chem-Biol Interact, 119-120, 503-511.
189. Richards P, Johnson M and Ray D. (2000). Identification of acylpeptide hydrolase as a sensitive site for reaction with organophosphorus compounds and a potential target for cognitive enhancing drugs. Mol Pharmacol, 58, 577-583.
190. Robinson JP. (1967). Chemical warfare. Sci J, 3, 33-40.
191. Rocha ES, Santos MD, Chechabo SR et al. (1999). Low concentrations of the organophosphate VX affect spontaneous and evoked transmitter release from hippocampal neurons: toxicological relevance of cholinesterase-independent actions. Toxicol Appl Pharmacol, 159, 31-40.
192. Romano JA, McDonough JH, Sheridan R et al. (2001). Health effects of low-level exposure to nerve agents. In: Chemical Warfare Agents: Toxicity at Low Levels (SM Somani and JARomani, eds), pp. 1-24. Boca Raton, FL, USA: CRC Press.
193. Rosenstock L, Keifer M, Daniell WE et al. (1991). Chronic central nervous system effects of acute organophosphate pesticide poisoning. Lancet, 338, 223-227.
194. Schoene K and Oldiges H. (1973). Efficacy of pyridinium salts against tabun and sarin poisoning in vivo and in vitro. Arch Int Pharmacodyn Ther, 204, 110-123.
195. Schoene K, Hochrainer D, Oldiges H et al. (1985). The protective effect of oxime pretreatment upon the inhalative toxicity of sarin and soman in rats. Fund Appl Toxicol, 5, 584-588.
196. Sekijima Y, Morita H and Yanagisawa N. (1997). Follow-up of sarin poisoning in Matsumoto. Ann Int Med, 127, 1042.
197. Sellström Å, Algers G and Karlsson B. (1985). Soman intoxication and the blood-brain barrier. Fund Appl Toxicol, 5, S122-S126.
198. Senanayake N (2001). Organophosphorus-induced delayed polyneuropathy. In: Organophosphates and Health (L Karalliedde, S Feldman, J Henry and T Marrs, eds), pp. 159-173. London, UK: Imperial College Press.
199. Senanayake N and Karalliedde L. (1987). Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. New Eng J Med, 316, 761-763.
200. Senanayake N and Karalliedde L (1992). The intermediate syndrome in anticholinesterase neurotoxicity. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs, eds), pp. 126-134. Oxford, UK: Butterworth-Heinemann.
201. Shih DM, Reddy S and Lusis AJ (2002). CHD and atherosclerosis: human epidemiological studies and transgenic mouse models. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects (LG Costa and CE Furlong, eds), pp. 93-123. Dordrecht, The Netherlands: Kluwer Academic Press.
202. Sidell FR. (1974). Soman and sarin: clinical manifestations and treatment of accidental poisoning. Clin Toxicol, 7, 1-17.
203. Silveira CLP, Eldefrawi AT and Eldefrawi ME. (1990). Putative M2 muscarinic receptors of rat heart have high affinity for organophosphorus anticholinesterases. Toxicol Appl Pharmacol, 103, 474-481.
204. Singer AW, Jaax NK, Graham JS et al. (1987). Cardiomyopathy in soman and sarin intoxicated rats. Toxicol Lett, 36, 243-249.
205. SIPRI (1971). Stockholm International Peace Research Institute, The Problem of Chemical and Biological Warfare, Volume 1, The Rise of CB Weapons. Stockholm, Sweden: Almqvist and Wiksell.
206. Slotkin TA (2005). Developmental neurotoxicity of organophosphorus: a case study of chlorpyrifos. In: Toxicology of Organophosphate and Carbamate Compounds (R Gupta, ed.), pp. 293-314. San Diego, CA, USA: Academic Press.
207. Smallbridge RC, Carr FE and Fein HG. (1991). Diisopropylfluorophosphate (DFP) reduces serum prolactin, thyrotropin, luteinizing hormone, and growth hormone and increases adrenocorticotropic and corticosterone in rats: involvement of dopaminergic and somatostatinergic as well as cholinergic pathways. Toxicol Appl Pharmacol, 108, 284-295.
208. Solberg Y and Belkin M. (1997). The role of excitotoxicity in organophosphorus nerve agents central poisoning. Trends Pharm Sci, 18, 183-185.
209. Somani SM and Husein K (2001). Low-level nerve agent toxicity under normal and stressful conditions. In: ChemicalWarfare Agents: Toxicity at Low Levels (SM Somani and JA Romano, eds), pp. 83-120. Boca Raton, FL, USA: CRC Press.
210. Spruit HET, Langenberg JP, Trap HC et al. (2000). Intravenous and inhalation toxicokinetics of sarin stereoisomers in atropinized guinea pigs. Toxicol Appl Pharmacol, 169, 249-254.
211. Stevenson IH (1990). Susceptibility of different age groups to toxic damage. In: Basic Science in Toxicology (GN Volans, J Sims, FM Sullivan and P Turner, eds), pp. 404-411. London, UK: Taylor & Francis.
212. St Omer VEV and Rottinghaus GE (1992). Biochemical determination of cholinesterase activity in biological fluids. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs, eds), pp. 15-27. Oxford, UK: Butterworth-Heinemann.
213. Subcommittee on Chronic Reference Doses for Selected Chemical-Warfare Agents (2000a). Summary. J Toxicol Clin Toxicol A, 59, 283-288.
214. Subcommittee on Chronic Reference Doses for Selected Chemical-Warfare Agents (2000b). Introduction. J Toxicol Clin Toxicol A, 59, 289-295.
215. Subcommittee on Chronic Reference Doses for Selected Chemical-Warfare Agents (2000c). Derivation of reference doses. J Toxicol Clin Toxicol A, 59, 297-301.
216. Subcommittee on Chronic Reference Doses for Selected Chemical-Warfare Agents (2000d). Evaluation of the army's interim reference dose for GA. J Toxicol Clin Toxicol A, 59, 303-311.
217. Subcommittee on Chronic Reference Doses for Selected Chemical-Warfare Agents (2000e). Evaluation of the army's interim reference dose for GB. J Toxicol Clin Toxicol A, 59, 313-321.
218. Subcommittee on Chronic Reference Doses for Selected Chemical-Warfare Agents (2000f). Evaluation of the army's interim reference dose for GD. J Toxicol Clin Toxicol A, 59, 323-330.
219. Subcommittee on Chronic Reference Doses for Selected Chemical-Warfare Agents (2000g). Evaluation of the army's interim reference dose for VX. J Toxicol Clin Toxicol A, 59, 331-338.
220. Sussman JL, Harel M, Frolow F et al. (1991). Atomic structure of acetylcholinesterase from Torpedo calfornica: a prototypic acetylcholine-binding protein. Science, 253, 872-879.
221. Swaminathan R and Widdop B (2001). Biochemical and toxicological investigation related to OP compounds. In: Organophosphates and Health (L Karalliedde, S Feldman, J Henry and T Marrs, eds), pp. 357-406. London, UK: Imperial College Press.
222. Talbot BG, Anderson DR, Harris LW et al. (1988). A comparison of in vivo and in vitro rates of aging of soman-inhibited erythrocyte acetylcholinesterase in different animal species. Drug Chem Toxicol, 11, 289-305.
223. Tang J, Carr RL and Chambers JE. (1999). Changes in rat brain cholinesterase activity and muscarinic receptor density during and after repeated oral exposure to chlorpyrifos in early postnatal development. Toxicol Sci, 51, 265-272.
224. Thompson CM and Richardson RJ (2004). In: Pesticides, Toxicology and International Regulation (TC Marrs and B Ballantyne, eds), pp. 89-127. Chichester, UK: John Wiley & Sons Ltd.
225. Tonduli LS, Testylier G, Pernot Marino I et al. (1999). Triggering of soman-induced seizures in rats: multiparametric analysis with special correlation between enzymatic, neurochemical and electrophysiological data. J Neurosci Res, 58, 464-473.
226. UK Ministry of Defence (1972). Medical Manual of Defence against Chemical Agents, JSP 312 A/24/Gen/4392, pp. 7-12. London, Edinburgh and Belfast, UK: Her Majesty's Stationary Office.
227. US EPA (1998). United States Environmental Protection Agency, Guidelines for developmental toxicity risk assessment. Fed Reg, 56, 63798-63826 (5 Dec).
228. Van der Schans M, Polhuijs M, van Dijk C et al. (2004). Retrospective detection of exposure to nerve agents: analysis of phosphofluoridates originating from fluoride-induced reactivation of phosphonylated BuChE. Arch Toxicol, 78, 508-524.
229. van Helden HPM, van der Wiel HJ, Zijlstra JJ et al. (1994). Comparison of the therapeutic effects and pharmacokinetics of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime following non-reactivatable acetylcholinesterase inhibition in rats. Arch Toxicol, 68, 224-230.
230. van Helden HPM, Trap HC, Kuijpers WC et al. (2004a). Low-level exposure of guinea pigs and marmosets to sarin vapour in air: lowestobservable-adverse-effect level (LOAEL) for miosis. J Appl Toxicol, 24, 59-68.
231. van Helden HPM, Vanwersh RAP, Kuijpers WC et al. (2004b). Low levels of sarin affect the EEG in marmoset monkeys: a pilot study. J Appl Toxicol, 24, 475-483.
232. Watson A, Bakshi K, Opresko D et al. (2005). Cholinesterase inhibitors as chemical warfare agents: community preparedness guidelines. In: Toxicology of Organophosphate and Carbamate Compounds. (R Gupta, ed.), pp. 47-68. San Diego, CA, USA: Academic Press.
233. Weger N and Szinicz L. (1981). Therapeutic effects of new oximes, benactyzine and atropine in soman poisoning: part I. Effects of various oximes in soman, sarin and VX poisoning in dogs. Fund Appl Toxicol, 1, 161-163.
234. Wehner JM, Smolen A and Smolen TN. (1985). Recovery of acetylcholinesterase activity after acute organophosphate treatment of CNS re-aggregate cultures. Fund Appl Toxicol, 5, 1104-1109.
235. WHO (1970). Technical Report, Health Aspects of Chemicals and Biological Weapons, Report of a World Health Organization Group of Consultants. Geneva, Switzerland: World Health Organization.
236. WHO (1986). Organophosphorus Insecticides: A General Introduction, Environmental Health Criteria 63. Geneva, Switzerland:World Health Organization.
237. Wills JH. (1961). Anticholinergic compounds as adjuncts to atropine in preventing lethality by sarin in the rabbit. J Med Pharm Chem, 3, 353-359.
238. Wilson BW, Hooper MJ, Hansen ME et al. (1992). Reactivation of organophosphorus inhibited AChE with oximes. In: Organophosphates, Chemistry, Fate and Effects (JE Chambers and PE Levi, eds), pp. 107-137. San Diego, CA, USA: Academic Press.
239. Wolthuis OL and Vanwersch RAP. (1984). Behavioral changes in the rat after low doses of cholinesterase inhibitors. Fund Appl Toxicol, 4, S195-S208.
240. Worek F, Eyer P and Szinicz L. (1998). Inhibition, reactivation and aging kinetics of cyclohexylmethylphosphonofluoridate-inhibited human cholinesterase. Arch Toxicol, 72, 580-587.
241. Yokoyama K, Araki S, Murata K et al. (1998). A preliminary study on delayed vestibulo-cerebellar effects of Tokyo subway sarin poisoning in relation to gender difference: frequency analysis of postural sway. J Occ Environ Med, 40, 17-21.
242. Young GD and Koplovitz I. (1995). Acute toxicity of cyclohexylmethylphosphonofluoridate (CPMF) in rhesus monkeys: serum biochemical and pharmacological changes. Arch Toxicol, 69, 379-383.